SEC-sourced researchBeta
RYTM
RHYTHM PHARMACEUTICALS, INC.
Company comparison ↗
Data passport
- CIK
- 0001649904
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 14, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 77,428,000.0000 | Feb 26, 2026 |
| December 2024 | 130,126,000.0000 | Feb 26, 2026 |
| December 2025 | 189,757,000.0000 | Feb 26, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 189,757,000.0000 | -196,539,000.0000 | -115,675,000.0000 | 480,196,000.0000 | 210,170,000.0000 | Feb 26, 2026 |
| December 2024 | 130,126,000.0000 | -260,602,000.0000 | -113,879,000.0000 | 392,273,000.0000 | 227,724,000.0000 | Feb 26, 2026 |
| December 2023 | 77,428,000.0000 | -184,678,000.0000 | -136,157,000.0000 | — | — | Feb 26, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $189.76M | December 2025 | Feb 26, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $130.13M | December 2024 | Feb 26, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$196.54M | December 2025 | Feb 26, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$115.68M | December 2025 | Feb 26, 2026 | 10-K |
| Total assetsAssets | $480.2M | December 2025 | Feb 26, 2026 | 10-K |
| Total liabilitiesLiabilities | $210.17M | December 2025 | Feb 26, 2026 | 10-K |